BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

# Abbott introduces next generation of heart valve technology designed to treat aortic stenosis in India

28 January 2025 | News

**This device is the latest iteration of the companyâ??s Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system**



Abbott, the global healthcare company, has announced the launch of Navitor Vision in India for the treatment of patients with symptomatic severe aortic stenosis who are at high or extreme surgical risk.

The device is the latest iteration of the company's Navitor transcatheter aortic valve implantation/replacement (TAVI/TAVR) system. The Navitor platform, known for its stable delivery, remarkable performance, and future readiness, has been enhanced with three large Vision markers for improved visibility and easier valve deployment during a TAVI/TAVR procedure. These markers help interventionists implant the device more accurately, while making the TAVI valve easier to see during the procedure.

Aortic stenosis is one of the most common and life-threatening heart valve diseases. Prior to TAVI, the standard of care for severe aortic stenosis was surgical aortic valve replacement, but not all patients were candidates for open-heart surgery.

Neeraj Singh, country manager for Abbott's structural heart business in India said, "For some people, open-heart surgery is considered a high-risk procedure due to the potential complications stemming from age, frailty or having multiple other diseases or conditions. TAVI serves as a less invasive alternative to surgical aortic valve replacement and can reduce symptoms and improve the life expectancy of patients with this condition. Abbott's Navitor Vision valve is an important addition to our range of treatments for structural heart issues, particularly for heart valve disease and offers hope to people who may not have other treatment choices."

The Navitor Vision valve comes in different sizes to fit heart openings (annulus) ranging from 19 mm to 27 mm and thereby fits almost all patients in need of TAVI. The device also has a dynamic sealing cuff that reduces the leaking of blood back to the heart. Navitor is implanted with Abbott's FlexNav delivery system, which offers a slim design, allowing treatment of people with vessels as small as 5.0 mm. The FlexNav catheter can accommodate different aortic anatomies for stable, predictable and accurate valve delivery and placement.